ANI PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
On August 24, 2026, Matthew J. Leonard, amember of the Board of Directors of the Company, adopted a Rule 10b5-1 trading plan. Mr. Leonard's Rule 10b5-1 trading plan provides for a term commencing on November 23, 2026 and ending on May 15, 2027 for the sale of up to 6,864 shares of common stock of the Company.
On September 4, 2026, Meredith Cook, Senior Vice President, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 trading plan. Ms. Cook’s Rule 10b5-1 trading plan provides for a term commencing on January 15, 2027 and ending on December 31, 2027 for the sale of up to 12,000 shares of common stock of the Company.
On September 14, 2026, Jeanne Thoma, amember of the Board of Directors of the Company, adopted a Rule 10b5-1 trading plan. Ms. Thoma's Rule 10b5-1 trading plan provides for a term commencing on January 1, 2027 and ending on June 1, 2027 for the sale of up to 8,752 shares of common stock of the Company.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.